Nobori Dual Antiplatelet Therapy as Appropriate Duration

A phase 4 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 3773 participants.

Also called NCT01514227

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; no masking; primary purpose treatment
Phase
Phase 4
Enrolled
  • 3,773 participants (enrolled count) (from the registry)
Sponsor
Associations for Establishment of Evidence in Interventions (from the registry)
Registry
  • NCT NCT01514227
Other papers using this trial's data
  • Dual Antiplatelet Therapy for 6 Versus 18 Months After Biodegradable Polymer Drug-Eluting Stent Implantation JACC. Cardiovascular interventions, 2017-06-26 DOI, PubMed 28641838

Courtesy of the U.S. National Library of Medicine.

Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
Japan (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01514227. Randomized; no masking; primary purpose treatment. Start 2011-12 (registry gives no type); primary completion 2016-06 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Nobori Dual Antiplatelet Therapy as Appropriate Duration
Intervention (Drug)
Aspirin or thienopyridine
Intervention (Drug)
Aspirin and thienopyridine
Lead sponsor
Associations for Establishment of Evidence in Interventions (class: other)

Record details

Record id
cardio:ct-nct01514227
Content hash
1f64d5063f37398199f110449103370ef43a2f681bdead955c5650d2a88ae265